We develop and commercialize innovative, clinically relevant diagnostic tools based on genetics.
Our products enable to:
Based on the most recent, validated knowledge in the field of health and genetics and proprietary algorithms.
7 November 2016
As of November 1st, 2016, Gene Predictis’ genetic tests Pill Protect® and Cypass® are reimbursed by supplementary healthcare cover PRIMEO from Helsana, the leading insurance group in Switzerland. These tests allow to evaluate, for every individual, the risk of adverse …
10 December 2015
Gene Predictis SA, a Swiss precision medicine company offering tools to optimize drug treatments, is a winner of the European Venture Contest 2015. The company was selected from over 1’000 companies in high technology sector, by an international investors jury …